Peeters, Marc
Price, Timothy
Taieb, Julien
Geissler, Michael
Rivera, Fernando
Canon, Jean-Luc
Pentheroudakis, George
Koukakis, Reija
Burdon, Peter
Siena, Salvatore
Funding for this research was provided by:
Amgen Inc.
Article History
Received: 24 December 2017
Revised: 24 May 2018
Accepted: 7 June 2018
First Online: 17 July 2018
Competing interests
: M.P. has received research funding from Amgen, Roche and Sirtex, and honoraria from Amgen, Merck Serono, Roche, Sanofi Aventis, Servier and Sirtex. T.P. has acted on advisory boards for Amgen, Merck Serono and Roche, and has received travel support from Amgen. J.T. has acted in consultancy and/or advisory roles for, and received honoraria from Amgen, Baxalta, Celgene, Eli Lilly, Merck, Roche, Sanofi, Servier and Sirtex. Michael Geissler has received research funding and acted in consultancy/advisory roles for Amgen, Bayer, Merck, Roche and Sanofi. F.R. has received research funding from and/or acted on advisory boards for Amgen, Bayer, Celgene, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Roche, Servier and Sanofi. J.-L.C. is a consultant/advisor for Amgen and Roche and has received institutional funding from Amgen, Novartis and Roche. G.P. has received research funding and advisory consulting fees from Amgen, Astra Zeneca, Boehringer, Bristol Myers Squibb, Lilly, Merck, MSD and Roche. R.K. is an employee of Amgen Ltd and owns restricted shares in Amgen. P.B. is an employee of Amgen (Europe) GmbH and owns shares in Amgen. S.S. is a member of advisory boards for Amgen, Bayer, Celgene, Eli Lilly, Ignyta, Merck, Merrimack, Novartis, Roche and Sanofi.
: All patients provided informed consent.
: The PRIME and PEAK studies were conducted in accordance with the Declaration of Helsinki. Study protocols were approved by an independent ethics committee at each study center.
: The PRIME (NCT00364013) and PEAK (NCT00819780) studies were supported by Amgen Inc.